Urine eosinophil‐derived neurotoxin: A potential marker of activity in select eosinophilic disorders
Allergy2022Vol. 78(1), pp. 258–269
Citations Over TimeTop 10% of 2022 papers
Michelle Makiya, Paneez Khoury, Fei Li Kuang, Alexis Dominique Mata, Sana Mahmood, Abbie Bowman, D. Nicolás Espinoza, Nicholas A. Kovacs, Thomas Brown, Nicole Holland, Lauren Wetzler, JeanAnne Ware, Anne‐Marie Dyer, Praveen Akuthota, Bruce S. Bochner, Vernon M. Chinchilli, Gerald J. Gleich, Carol A. Langford, Peter A. Merkel, Ulrich Specks, Peter F. Weller, Michael E. Wechsler, Calman Prussin, Michael P. Fay, Amy D. Klion
Abstract
Measurement of EGP in urine is noninvasive and unaffected by cellular lysis. Although plasma and urine EDN concentrations showed a similar pattern following benralizumab and mepolizumab treatment, the lack of correlation between AEC or prednisone dose and uEDN concentrations suggests that measurement of uEDN may provide a potential biomarker of disease activity in patients with HES and EGPA.
Related Papers
- → Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab(2008)570 cited
- → Localization of eosinophil cationic protein, major basic protein, and eosinophil peroxidase in human eosinophils by immunoelectron microscopic technique.(1986)95 cited
- → Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab(2008)19 cited
- → M239 SUCCESSFUL LIVER TRANSPLANTATION IN A PATIENT WITH HYPEREOSINOPHILIC SYNDROME TREATED WITH MEPOLIZUMAB(2020)
- → The anti-interleukin-5 monoclonal antibody, mepolizumab*, may have significant therapeutic potential for hypereosinophilic syndrome,(2004)